54 completed, 10 terminated, 5 unknown, 3 recruiting. 77 Phase 2, 9 Phase 1, 8 Phase 3.
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RELEASE Ph2 RT-310 BPH Study RT-310 PK, Placebo, RT-310 - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Not yet recruiting | Resurge Therapeutics Inc. | 86 | 2027-01-01 | 2026-11-10 |
| Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention Teverelix DP, Teverelix DP Placebo - Acute Urinary Retention, Benign Prostate Hypertrophy(BPH) | Phase 2 | Not yet recruiting | Antev Ltd. | 126 | 2026-09-01 | 2026-07-29 |
| RADA16 for Aquablation Day Case PuraStat - Hematuria, Benign Prostatic Hyperplasia | Phase 2 | Completed | NYU Langone Health | 24 | 2026-05-14 | 2026-11-09 |
| New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia raloxifene, Finasteride - BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 242 | 2025-12-03 | 2026-03-23 |
| RT-310 Safety and Feasibility BPH Study RT-310 - BPH (Benign Prostatic Hyperplasia) | Phase 1 / Phase 2 | Active not recruiting | Resurge Therapeutics Inc. | 20 | 2025-03-13 | 2026-10-30 |
| Evaluation of the Functional Outcomes After Bilateral, 3D Ultrasound-guided Focal Thermal Ablation of the Prostate Transition Zone, in Patients With Benign Prostatic Hyperplasia-related Obstruction Targeted Microwave Ablation - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 8 | 2024-04-24 | 2026-10-01 |
| Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer Elidah Device - Urinary Urge Incontinence, Stress Urinary Incontinence | Phase 2 | Recruiting | National Cancer Institute (NCI) | 41 | 2024-02-15 | 2026-11-10 |
| Effects of TNF Blockade on Human BPH/LUTS Adalimumab - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Recruiting | Endeavor Health | 70 | 2024-01-24 | 2024-11-21 |
| The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet, silodosin 8 mg capsule - Prostatic Hyperplasia | Phase 2 | Completed | Beni-Suef University | 140 | 2023-02-01 | 2024-03-20 |
| Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Merit Medical Embospheres, Radiation Therapy - Prostate Carcinoma, Benign Prostatic Hyperplasia | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-02-23 | 2026-07-30 |
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Teverelix Evaluated in Advanced Prostate Cancer teverelix TFA 120 mg, teverelix TFA 180 mg - Prostatic Adenoma | Phase 2 | Completed | Antev Ltd. | 50 | 2021-03-04 | 2024-07-23 |
| Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | REMD Medical Technology | 160 | 2020-08-20 | 2022-09-07 |
| Evaluation of the Effect of Garcinia in Combination With Chromium on the Clinical Outcomes of Patients With LUTS/BPH Chromax, Sildosin Group, Placebo Group - Prostatic Hyperplasia | Phase 2 | Unknown | Benha University | 120 | 2020-08-01 | 2022-11-10 |
| The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Taipei Veterans General Hospital, Taiwan | 23 | 2019-03-06 | 2020-04-13 |
| Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study Mirabegron, placebo - BPH, Erectile Dysfunction | Phase 2 | Unknown | Mansoura University | 50 | 2018-08-01 | 2019-09-04 |
| Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | OPKO Health, Inc. | 114 | 2018-02-21 | 2021-09-16 |
| Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel - Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy | Phase 2 | Completed | Urotronic Inc. | 80 | 2017-12-19 | 2025-11-26 |
| Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement DC Lumi Bead, BTG - Benign Prostatic Hyperplasia | Phase 2 | Unknown | University Hospital Southampton NHS Foundation Trust | 23 | 2017-06-02 | 2020-10-22 |
| Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) Fedovapagon 2 mg, Placebo - Nocturia | Phase 2 / Phase 3 | Completed | Vantia Ltd | 432 | 2016-03-01 | 2018-10-31 |
Showing 20 of 77. Sign in to see all of them.
Lower Urinary Tract Symptoms (10) · Prostatic Neoplasms (6) · Erectile Dysfunction (2) · Nocturia (2) · Prostatic Diseases (2) · Eunuchism (1) · Genital Diseases (1) · Hematuria (1) · Infertility, Male (1) · Lymphoma, Follicular (1) · Muscular Atrophy (1) · Prostatism (1) · Prostatitis (1) · Sarcopenia (1)
Genital Diseases, Male (77) · Male Urogenital Diseases (77) · Urogenital Diseases (77) · Genital Diseases (76) · Prostatic Diseases (75) · Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (15) · Urological Manifestations (14) · Neoplasms (7) · Genital Neoplasms, Male (6) · Neoplasms by Site (6) · Urogenital Neoplasms (6) · Lower Urinary Tract Symptoms (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
Tamsulosin (7) · Botulinum Toxins, Type A (6) · Tadalafil (5) · Finasteride (3) · Saline Solution (3) · silodosin (3) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (2) · PRX302 (2) · Sodium Chloride (2) · Talaporfin (2) · Transurethral Resection of Prostate (2) · Vardenafil Dihydrochloride (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · ozarelix (2) · Acupuncture Therapy (1)
Eli Lilly and Company (6) · Allergan (3) · Antev Ltd. (2) · Astellas Pharma Inc (2) · Bayer (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Light Sciences Oncology (2) · Pfizer (2) · QLT Inc. (2) · Resurge Therapeutics Inc. (2) · Sophiris Bio Corp (2) · Spectrum Pharmaceuticals, Inc (2) · VA Office of Research and Development (2) · American Medical Systems (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (35) · Canada (10) · Germany (7) · France (5) · South Korea (5) · Australia (4) · Czechia (4) · Italy (4) · Japan (4) · Slovakia (4) · United Kingdom (4) · Egypt (3) · Greece (3) · Poland (3) · Russia (3)
Ahmed Shokeir, PhD (1) · Albertas Ulys, MD (1) · Alexander P Glaser, M.D. (1) · Allan J Pantuck, MD, MS, FACS (1) · Andrey A Pulin, MD, PhD (1) · Andrey Z Vinarov, MD, PhD, Prof (1) · Anna C. Ferrari, MD (1) · Aria Olumi, MD (1) · Christopher Kelly, MD (1)
PMID 21791356, PMID 12893330, PMID 15126771, PMID 18461049, PMID 18722631, PMID 19409693, PMID 20163842, PMID 21943105, PMID 23098762, PMID 23537687, PMID 23593139, PMID 23877659, PMID 24012740, PMID 24326421, PMID 25873370, PMID 26299520, PMID 26945662, PMID 27842331, PMID 28053292, PMID 29228755, PMID 29398594, PMID 37354260, PMID 38311868, PMID 40209997
R01DK135516 (1), R01DK142211 (1), U01DK060817 (1)